Pharmaceuticals, Biotechnology and Life Sciences
– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led…
WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody…
PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company…
NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) — Algae-C Inc. (“Algae-C”) today issues a correction to its earlier release announcing its…
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ:…
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing…
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…